Growth Metrics

Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)

Barinthus Biotherapeutics filings provide 1 years of Convertible Debt readings, the most recent being $44.7 million for Q4 2020.

  • On a quarterly basis, Convertible Debt changed N/A to $44.7 million in Q4 2020 year-over-year; TTM through Dec 2020 was $44.7 million, a N/A change, with the full-year FY2020 number at $44.7 million, changed N/A from a year prior.
  • Convertible Debt hit $44.7 million in Q4 2020 for Barinthus Biotherapeutics.
  • In the past five years, Convertible Debt ranged from a high of $44.7 million in Q4 2020 to a low of $44.7 million in Q4 2020.